About Adverum Biotechnologies (NASDAQ:ADVM)
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, discovers and develops novel medicines for patients suffering from rare and ocular diseases. The company's pipeline includes product candidates, which are used for the treatment of wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development for wAMD diseases; and ADVM-043 for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates that comprise ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio-4.88
Forward P/E Ratio-4.81
Sales & Book Value
Annual Sales$1.85 million
Price / Sales178.48
Price / CashN/A
Book Value$4.09 per share
Price / Book1.54
EPS (Most Recent Fiscal Year)($1.29)
Return on Equity-29.61%
Return on Assets-27.04%
Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions
What is Adverum Biotechnologies' stock symbol?
Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."
How were Adverum Biotechnologies' earnings last quarter?
Adverum Biotechnologies (NASDAQ:ADVM) issued its earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. The biotechnology company had revenue of $0.46 million for the quarter. Adverum Biotechnologies had a negative net margin of 3,036.61% and a negative return on equity of 29.61%. View Adverum Biotechnologies' Earnings History.
When is Adverum Biotechnologies' next earnings date?
What price target have analysts set for ADVM?
3 analysts have issued 12 month price targets for Adverum Biotechnologies' shares. Their predictions range from $3.50 to $12.00. On average, they anticipate Adverum Biotechnologies' share price to reach $7.1667 in the next twelve months. View Analyst Ratings for Adverum Biotechnologies.
What are Wall Street analysts saying about Adverum Biotechnologies stock?
Here are some recent quotes from research analysts about Adverum Biotechnologies stock:
- 1. According to Zacks Investment Research, "Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. " (3/28/2018)
- 2. Chardan Capital analysts commented, "We note PRVs have in 2017 sold for: 1) $130 mm to Ultragenyx Pharmaceutical (unrated), announced 18 December 2017; 2) $125 mm to BioMarin Pharmaceutical (unrated), announced 27 November 2017, and 3) $125 mm to Sarepta Therapeutics (unrated), announced 21 February 2017. We understand Spark will announce the pricing of Luxturna in January, and that the drug will be available in late 1Q18. The Midwest CEPAC will convene to discuss the Institute for Clinical and Economic Review (ICER) document on Luxturna, on 25 January 2018. Luxturna’s approval is an important (+) for GT, particularly for AAV-based ophthalmology companies. We understand Luxturna is the first gene therapy approved in the US for a genetic disease, the first in vivo and AAV-based gene therapy approved in the US, and the first pharmacologic treatment approved for an inherited retinal disease (IRD)." (12/19/2017)
Who are some of Adverum Biotechnologies' key competitors?
Some companies that are related to Adverum Biotechnologies include Jounce Therapeutics (JNCE), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), EntreMed (CASI), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), PDL Biopharma (PDLI), Agenus (AGEN), Nightstar Therapeutics (NITE), Idera Pharmaceuticals (IDRA), Solid Biosciences (SLDB), Cellular Biomedicine (CBMG), NantKwest (NK), Allena Pharmaceuticals (ALNA), Fennec Pharmaceuticals (FENC) and Osiris Therapeutics (OSIR).
Who are Adverum Biotechnologies' key executives?
Adverum Biotechnologies' management team includes the folowing people:
- Dr. Amber Salzman Ph.D., Chief Exec. Officer, Pres and Director (Age 56)
- Dr. Mitchell H. Finer Ph.D., Co-Founder and Director (Age 59)
- Dr. Mehdi Gasmi Ph.D., Chief Science and Technology Officer (Age 51)
- Ms. Leone D. Patterson, Chief Financial Officer (Age 55)
- Dr. Jennifer Cheng Ph.D., J.D., VP, Gen. Counsel and Sec. (Age 45)
Has Adverum Biotechnologies been receiving favorable news coverage?
Press coverage about ADVM stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adverum Biotechnologies earned a news impact score of 0.16 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 47.44 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Adverum Biotechnologies?
Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adverum Biotechnologies' stock price today?
One share of ADVM stock can currently be purchased for approximately $6.30.
How big of a company is Adverum Biotechnologies?
Adverum Biotechnologies has a market capitalization of $341.95 million and generates $1.85 million in revenue each year. The biotechnology company earns $-56,140,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Adverum Biotechnologies employs 78 workers across the globe.
How can I contact Adverum Biotechnologies?
Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]
MarketBeat Community Rating for Adverum Biotechnologies (ADVM)MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
Adverum Biotechnologies (NASDAQ:ADVM) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Adverum Biotechnologies (NASDAQ ADVM) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.80%
Institutional Ownership Percentage: 36.69%
Adverum Biotechnologies (NASDAQ ADVM) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|6/8/2015||Mehdi Gasmi||VP||Sell||500||$38.64||$19,320.00|| |
|6/8/2015||Paul Wachter||Director||Sell||1,192||$38.64||$46,058.88|| |
|5/26/2015||Paul Wachter||Director||Sell||1,192||$36.94||$44,032.48|| |
|5/22/2015||Steven Daniel Schwartz||Director||Sell||16,875||$38.38||$647,662.50|| |
|5/13/2015||Linda Bain||CFO||Sell||285||$34.94||$9,957.90|| |
|5/13/2015||Mark S Blumenkranz||Director||Sell||715||$34.94||$24,982.10|| |
|5/8/2015||Steven Daniel Schwartz||Director||Sell||17,250||$33.05||$570,112.50|| |
|4/28/2015||Mehdi Gasmi||VP||Sell||1,000||$35.67||$35,670.00|| |
|4/27/2015||Paul Wachter||Director||Sell||1,192||$35.61||$42,447.12|| |
|4/23/2015||Steven Daniel Schwartz||Director||Sell||16,875||$38.62||$651,712.50|| |
|4/21/2015||Mehdi Gasmi||VP||Sell||1,000||$39.21||$39,210.00|| |
|4/20/2015||Paul Wachter||Director||Sell||1,192||$40.19||$47,906.48|| |
|4/16/2015||Mark S Blumenkranz||Director||Sell||25,000||$41.59||$1,039,750.00|| |
|4/14/2015||Zygtech, Llc||Major Shareholder||Sell||25,000||$39.55||$988,750.00|| |
|4/13/2015||Paul Wachter||Director||Sell||1,192||$39.34||$46,893.28|| |
|4/9/2015||Steven Daniel Schwartz||Director||Sell||17,250||$39.73||$685,342.50|| |
|4/7/2015||Hans Hull||SVP||Sell||27,500||$38.60||$1,061,500.00|| |
|4/7/2015||Mehdi Gasmi||VP||Sell||9,000||$38.60||$347,400.00|| |
|8/5/2014||James E Flynn||Insider||Buy||1,334,467||$23.92||$31,920,450.64|| |
|8/5/2014||Regeneron Pharmaceuticals Inc||Major Shareholder||Buy||588,235||$17.00||$9,999,995.00|| |
Adverum Biotechnologies (NASDAQ ADVM) News Headlines
|Are Earnings Prospects Improving For Loss-Making Adverum Biotechnologies Inc’s (NASDAQ:ADVM)?|
finance.yahoo.com - April 20 at 5:26 PM
|Adverum Biotechnologies (ADVM) Expected to Announce Earnings of -$0.29 Per Share|
www.americanbankingnews.com - April 15 at 3:15 PM
|Adverum Biotechnologies (ADVM) Upgraded by BidaskClub to "Strong-Buy"|
www.americanbankingnews.com - April 12 at 10:47 AM
|Adverum Biotechnologies' (ADVM) Hold Rating Reiterated at Chardan Capital|
www.americanbankingnews.com - April 9 at 1:19 PM
|Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis|
www.nasdaq.com - April 9 at 8:12 AM
|Research Report Identifies Teck Resources, Adverum Biotechnologies, BeiGene, IPG Photonics, Arsanis, and G1 THERAPEUTICS with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement|
finance.yahoo.com - April 9 at 8:12 AM
|Adverum Biotechnologies: Gene Therapy Company And Our New Buy|
seekingalpha.com - April 8 at 9:25 AM
|Adverum Biotechnologies Inc (ADVM) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - April 4 at 3:24 AM
|Adverum Biotechnologies (ADVM) Rating Lowered to Strong Sell at ValuEngine|
www.americanbankingnews.com - March 31 at 4:56 PM
|Adverum Biotechnologies (ADVM) Lifted to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - March 29 at 9:36 PM
|Zacks: Brokerages Expect Adverum Biotechnologies Inc (ADVM) to Post -$0.29 Earnings Per Share|
www.americanbankingnews.com - March 29 at 7:24 PM
|Adverum Biotechnologies (ADVM) Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - March 28 at 4:25 PM
|4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End|
finance.yahoo.com - March 27 at 8:20 AM
|Adverum Biotechnologies (ADVM) Upgraded to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 23 at 4:34 PM
|Adverum Biotechnologies (ADVM) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - March 22 at 4:32 PM
|Adverum Biotechnologies (ADVM) Cut to Hold at Zacks Investment Research|
www.americanbankingnews.com - March 15 at 4:46 PM
|Adverum: A Lot Done, A Lot More To Do - Seeking Alpha|
seekingalpha.com - March 15 at 8:10 AM
|Adverum Biotechnologies (ADVM) Raised to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 14 at 5:32 PM
| Brokerages Expect Adverum Biotechnologies Inc (ADVM) Will Announce Earnings of -$0.31 Per Share|
www.americanbankingnews.com - March 12 at 3:55 PM
|Adverum Biotechnologies (ADVM) Downgraded by BidaskClub to Buy|
www.americanbankingnews.com - March 10 at 4:36 PM
|Adverum Biotechnologies Inc (ADVM) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - March 10 at 4:14 AM
|Adverum Biotechnologies (ADVM) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS|
www.americanbankingnews.com - March 7 at 8:14 AM
|Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)|
globenewswire.com - March 7 at 8:11 AM
|Adverum Biotechnologies (ADVM) Presents At Raymond James 39th Annual Institutional Investors Conference - Slideshow|
seekingalpha.com - March 6 at 5:44 PM
|Adverum Biotechnologies Reports Fourth Quarter 2017 Financial Results and Provides Corporate Update|
finance.yahoo.com - March 6 at 5:44 PM
|Adverum Biotechnologies Inc (ADVM) Sees Large Increase in Short Interest|
www.americanbankingnews.com - March 3 at 3:26 AM
|Adverum Biotechnologies Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 ... - GlobeNewswire (press release)|
globenewswire.com - February 27 at 8:13 AM
|BRIEF-Adverum Biotechnologies Announces Completion Of Dosing Of First Cohort|
www.reuters.com - February 26 at 5:49 PM
|Adverum Biotechnologies Announces Completion of Dosing of First Cohort of Patients in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 Gene Therapy for A1AT Deficiency|
finance.yahoo.com - February 26 at 5:49 PM
|Is a Beat in Store for Adverum (ADVM) This Earnings Season?|
finance.yahoo.com - February 26 at 5:49 PM
|Adverum Biotechnologies (ADVM) Scheduled to Post Earnings on Monday|
www.americanbankingnews.com - February 26 at 3:20 AM
|Adverum Biotechnologies Inc (ADVM) Expected to Post Earnings of -$0.34 Per Share|
www.americanbankingnews.com - February 23 at 5:30 PM
|Piper Jaffray Companies Begins Coverage on Adverum Biotechnologies (ADVM)|
www.americanbankingnews.com - February 17 at 7:40 PM
|Adverum Biotechnologies Announces Closing of $69 Million Public Offering|
finance.yahoo.com - February 13 at 9:03 AM
|Adverum Biotechnologies (ADVM) Prices 8.89M Common Stock Offering at $6.75/Share|
www.streetinsider.com - February 9 at 9:13 AM
|Adverum Biotechnologies Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - February 8 at 8:07 AM
|Adverum Biotechnologies Announces Pricing of $60 Million Public Offering of Common Stock|
finance.yahoo.com - February 8 at 8:07 AM
|Zacks: Analysts Anticipate Adverum Biotechnologies Inc (ADVM) to Announce -$0.35 Earnings Per Share|
www.americanbankingnews.com - February 6 at 5:08 PM
|Adverum Biotechnologies (ADVM) Jumps: Stock Rises 7.9%|
finance.yahoo.com - January 30 at 3:40 PM
|3 Biotech Stocks With Jaw-Dropping Growth Potential|
finance.yahoo.com - January 29 at 9:09 AM
|Adverum Biotechnologies (ADVM) Lifted to "Sell" at ValuEngine|
www.americanbankingnews.com - January 25 at 11:16 PM
|Comparing Capricor Therapeutics (CAPR) & Adverum Biotechnologies (ADVM)|
www.americanbankingnews.com - January 23 at 9:28 PM
|Adverum Biotechnologies (ADVM) Announces Progress Update and 2018 Outlook|
www.streetinsider.com - January 5 at 10:58 AM
|Adverum Biotechnologies (ADVM) Announces Progress Update and 2018 Outlook - StreetInsider.com|
www.streetinsider.com - January 4 at 3:35 PM
|Adverum Biotechnologies Provides 2018 Outlook|
finance.yahoo.com - January 4 at 11:18 AM
|-$0.35 Earnings Per Share Expected for Adverum Biotechnologies Inc (ADVM) This Quarter|
www.americanbankingnews.com - January 3 at 11:30 PM
|Financial Contrast: Adverum Biotechnologies (ADVM) & Summit Therapeutics (SMMT)|
www.americanbankingnews.com - January 3 at 12:30 PM
|Adverum Biotechnologies (ADVM) Commences First Patient in the ADVANCE Phase 1/2 Clinical Trial of ADVM-043 for A1AT Deficiency|
www.streetinsider.com - December 29 at 10:52 AM
|Adverum Biotechnologies Doses First Patient in the ADVANCE ... - GlobeNewswire (press release)|
globenewswire.com - December 28 at 3:09 PM
|ETFs with exposure to Adverum Biotechnologies, Inc. : December 28, 2017|
finance.yahoo.com - December 28 at 3:09 PM
Adverum Biotechnologies (NASDAQ:ADVM) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Adverum Biotechnologies (NASDAQ:ADVM) Income Statement, Balance Sheet and Cash Flow Statement
Adverum Biotechnologies (NASDAQ ADVM) Stock Chart for Saturday, April, 21, 2018